Evaluation of Prophylactic Anticoagulants Application Practice for High-Risk Surgical Patients at Al-Thawra Hospital, Sana'a
DOI:
https://doi.org/10.65693/j21umas.2024.v3i1.199Keywords:
Prophylactic Anticoagulants, High-Risk Surgical Patients, Venous Thromboembolism (VTE), Al-Thawra Hospital.Abstract
-
Background: Through clinical practice, it has been noticed that the number of patients who had DVT and PE during their hospital admission period has increased, especially among high-risk surgical patients. Physicians may not be aware of or may not consistently use up-to-date evidence-based prevention guidelines. There is an abundance of evidence documenting the underutilization of prophylactic measures in hospitalized patients.
-
Objective: The study aimed to determine the percentage of prophylactic anticoagulant application for high-risk surgical patients.
-
Methods: A retrospective observational research approach was followed using a special questionnaire. Data were collected from files of patients with high risk for VTE who were admitted to the Orthopedic, Gynecological and Neurosurgical surgical departments at Al-Thawra hospital, Sana'a, during the period from 1/1/2014 to 31/12/2014. All selected patient's files were screened for sociodemographic characteristics, other risk factors of DVT, and medications list.
-
Results: A total of 99 patients files were enrolled in the study, which were divided into 33 patients for every department (Orthopedic, Gynecological and Neurosurgical). The results showed that 68% of the studied high-risk surgical patients were given prophylactic anticoagulants and the percentages of prophylactic anticoagulants application in each department (Orthopedic, Gynecological and Neurosurgical) were 60.6%, 72.7% and 69.7%, respectively. In the Orthopedic department, 66.6% of the patients were male while in the Neurosurgical department 72.7% of the patients were male. Patients younger than 40 years old in the Orthopedic, Gynecological and Neurosurgical departments were 18.2%, 51.5% & 42.4% respectively.
-
Conclusion: According to the current study findings, the percentage of prophylactic anticoagulants application for high-risk surgical patient was low in comparison with that of the developed countries, such as Germany 92%, Hungary 87%, Spain 82% and Switzerland 81%.
References
Longo, Dan; Fauci, Anthony; Kasper, Dennis; Hauser, Stephen; Jameson, J.; and Loscalzo, Joseph. Harrisons Manual of Medicine, 18th Edition. US: Professional, 2014 chpter 14 Prevention of Venous Thromboembolic Disease. McGraw-Hill 2012.Current. McPhee, S. J., Papadakis, M. A., & Rabow, M. W. (2014). Current medical diagnosis & treatment 2014. 53rd ed. New York, McGraw-Hill Medical.Series Editor: Kamal M.F. Itani, MD (Primary Prophylaxis of Venous Thromboembolism in Surgical Patients). Bergmann JF, Cohen AT, Tapson VF, Goldhaber SZ, Kakkar AK, Deslandes B, Huang W. Anderson FA Jr; ENDORSE Investigators. Venous thromboembolism risk and prophylaxis in hospitalised medically ill patients. The ENDORSE Global Survey. Thromb Haemost. 2010 Apr;103(4):736-48. doi: 10.1160/TH09-09-0667. Epub 2010 Feb 2. PMID: 20135072. multinational a (ENDORSE), cross-sectional study: Results from the Indian subset data. Geerts WH. Prevention of venous thromboembolism in high-risk patients. Hematology Am Soc Hematol Educ Program 2006:462-6 jurnal of the American colleague of chest physicians. Francis CW. Clinical practice. Prophylaxis for thromboembolism in hospitalizedmedical patients. N Engl J Med. 2007;356 (14): 1438-1444. Geerts WH. Prevention of venous thromboembolism in high-risk patients. Hematology Am Soc Hematol Educ Program 2006:462-6 jurnal of the American colleague of chest physicians. Francis CW. Clinical practice. Prophylaxis for thromboembolism in hospitalizedmedical patients. N Engl J Med. 2007;356 (14): 1438-1444. Essam AE, Sharif G, Al-Hameed F. Venous thromboembolism-related mortality and morbidity in King Fahd General Hospital, Jeddah, Kingdom of Saudi Arabia. Ann Thorac Med [serial online] 2011 [cited 2014 May 4];6:193-8. Availablefrom: http://www.thoracicmedicine.org/text.asp?2011/6/4/193/84772. Dennis R15. J, Roa JH, Villadiego J, Méndez F, Vieda E, Restrepo H. Venous thromboembolism prophylaxis in Colombian surgical and medical patients: results for Colombia of the ENDORSE study. Biomedica 2011; 31: 200-8. Cohen AT, Davidson BL, Gallus AS,et al; ARTEMIS investigators. Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: Randomised placebo controlled trial. BMJ. 2006;332(7537):325-329. Leizorovicz A, Cohen AT, Turpie AG, et al; PREVENT Medical Thromboprophylaxis Study Group. Randomized, placebocontrolled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. Circulation. 2004;110(7):874-879. Samama MM, Cohen AT, Darmonn JY, et al. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in Medical Patients with Enoxaparin Study Group. N Engl J Med. 1999;341(11):793-800.
Downloads
Published
Issue
Section
License
Copyright (c) 2024 Akram Beshr، Abdulhafed Al-Selwi (المؤلف)
This work is licensed under a Creative Commons Attribution 4.0 International License.
This is an open-access journal which means that all content is freely available without charge to the user or their institution. Users are allowed to read, download, copy, distribute, print, search, or link to the full texts of the articles, or use them for any other lawful purpose, provided the original work is properly cited. All articles are licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0).
